Clinical trial
Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar…
NCT00216723 · Korea Otsuka Pharmaceutical Co., Ltd., Industry · Completed
Key facts
| NCT number | NCT00216723 |
|---|---|
| Title | Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder |
| Official title | Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder |
| Lead sponsor | Korea Otsuka Pharmaceutical Co., Ltd., Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Schizophrenia, Bipolar Disorder |
| Intervention type | Drug |
| Interventions | Aripiprazole |
| Enrollment | 3,000 |
| Start date | Apr 1, 2004 |
| Completion | Dec 1, 2009 |
| First posted | Sep 22, 2005 |
| Last update posted | Oct 23, 2013 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: